Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Vericel Corporation stock | 25.67

Own Vericel Corporation stock in just a few minutes.

Posted

Fact checked

Vericel Corporation is a biotechnology business based in the US. Vericel Corporation shares (VCEL) are listed on the NASDAQ and all prices are listed in US Dollars. Vericel Corporation employs 241 staff and has a trailing 12-month revenue of around USD$118.3 million.

How to buy shares in Vericel Corporation

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Vericel Corporation. Find the stock by name or ticker symbol: VCEL. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Vericel Corporation reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$25.67, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Vericel Corporation, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Vericel Corporation. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Vericel Corporation's share price?

Since the stock market crash in March caused by coronavirus, Vericel Corporation's share price has had significant positive movement.

Its last market close was USD$25.67, which is 25.15% up on its pre-crash value of USD$19.215 and 278.61% up on the lowest point reached during the March crash when the shares fell as low as USD$6.78.

If you had bought USD$1,000 worth of Vericel Corporation shares at the start of February 2020, those shares would have been worth USD$438.67 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,521.72.

Vericel Corporation share price

Use our graph to track the performance of VCEL stocks over time.

Vericel Corporation shares at a glance

Information last updated 2020-11-19.
Latest market close USD$25.67
52-week range USD$6.78 - USD$26.22
50-day moving average USD$21.4925
200-day moving average USD$17.2024
Wall St. target price USD$29.25
PE ratio 2579
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.003

Buy Vericel Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Vericel Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vericel Corporation price performance over time

Historical closes compared with the close of $25.67 from 2020-11-16

1 week (2020-11-15) N/A
1 month (2020-10-26) 26.20%
3 months (2020-08-22) N/A
6 months (2020-05-22) N/A
1 year (2019-11-22) N/A
2 years (2018-11-22) N/A
3 years (2017-11-22) N/A
5 years (2015-11-22) N/A

Is Vericel Corporation under- or over-valued?

Valuing Vericel Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Vericel Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Vericel Corporation's P/E ratio

Vericel Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2579x. In other words, Vericel Corporation shares trade at around 2579x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Vericel Corporation's EBITDA

Vericel Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$1.5 million.

The EBITDA is a measure of a Vericel Corporation's overall financial performance and is widely used to measure a its profitability.

Vericel Corporation financials

Revenue TTM USD$118.3 million
Gross profit TTM USD$80.3 million
Return on assets TTM -0.3%
Return on equity TTM 0.14%
Profit margin 0.12%
Book value $2.53
Market capitalisation USD$1.1 billion

TTM: trailing 12 months

Shorting Vericel Corporation shares

There are currently 4.2 million Vericel Corporation shares held short by investors – that's known as Vericel Corporation's "short interest". This figure is 0.5% down from 4.2 million last month.

There are a few different ways that this level of interest in shorting Vericel Corporation shares can be evaluated.

Vericel Corporation's "short interest ratio" (SIR)

Vericel Corporation's "short interest ratio" (SIR) is the quantity of Vericel Corporation shares currently shorted divided by the average quantity of Vericel Corporation shares traded daily (recently around 458848.52780807). Vericel Corporation's SIR currently stands at 9.17. In other words for every 100,000 Vericel Corporation shares traded daily on the market, roughly 9170 shares are currently held short.

However Vericel Corporation's short interest can also be evaluated against the total number of Vericel Corporation shares, or, against the total number of tradable Vericel Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vericel Corporation's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Vericel Corporation shares in existence, roughly 90 shares are currently held short) or 0.0934% of the tradable shares (for every 100,000 tradable Vericel Corporation shares, roughly 93 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Vericel Corporation.

Find out more about how you can short Vericel Corporation stock.

Vericel Corporation share dividends

We're not expecting Vericel Corporation to pay a dividend over the next 12 months.

Have Vericel Corporation's shares ever split?

Vericel Corporation's shares were split on a 1:20 basis on 16 October 2013. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Vericel Corporation shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Vericel Corporation shares which in turn could have impacted Vericel Corporation's share price.

Vericel Corporation share price volatility

Over the last 12 months, Vericel Corporation's shares have ranged in value from as little as $6.78 up to $26.22. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vericel Corporation's is 3.0581. This would suggest that Vericel Corporation's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Vericel Corporation overview

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. It markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to dilated cardiomyopathy. In addition, its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for debridement of severe thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site